These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1033 related articles for article (PubMed ID: 20813948)
1. Spiroindolones, a potent compound class for the treatment of malaria. Rottmann M; McNamara C; Yeung BK; Lee MC; Zou B; Russell B; Seitz P; Plouffe DM; Dharia NV; Tan J; Cohen SB; Spencer KR; González-Páez GE; Lakshminarayana SB; Goh A; Suwanarusk R; Jegla T; Schmitt EK; Beck HP; Brun R; Nosten F; Renia L; Dartois V; Keller TH; Fidock DA; Winzeler EA; Diagana TT Science; 2010 Sep; 329(5996):1175-80. PubMed ID: 20813948 [TBL] [Abstract][Full Text] [Related]
2. Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4. Turner H Future Med Chem; 2016; 8(2):227-38. PubMed ID: 26824174 [TBL] [Abstract][Full Text] [Related]
3. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Spillman NJ; Allen RJ; McNamara CW; Yeung BK; Winzeler EA; Diagana TT; Kirk K Cell Host Microbe; 2013 Feb; 13(2):227-37. PubMed ID: 23414762 [TBL] [Abstract][Full Text] [Related]
4. Microbiology. Is the tide turning for new malaria medicines? Wells TN Science; 2010 Sep; 329(5996):1153-4. PubMed ID: 20813940 [No Abstract] [Full Text] [Related]
5. A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609. Zhang R; Suwanarusk R; Malleret B; Cooke BM; Nosten F; Lau YL; Dao M; Lim CT; Renia L; Tan KS; Russell B J Infect Dis; 2016 Jan; 213(1):100-4. PubMed ID: 26136472 [TBL] [Abstract][Full Text] [Related]
6. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. Yeung BK; Zou B; Rottmann M; Lakshminarayana SB; Ang SH; Leong SY; Tan J; Wong J; Keller-Maerki S; Fischli C; Goh A; Schmitt EK; Krastel P; Francotte E; Kuhen K; Plouffe D; Henson K; Wagner T; Winzeler EA; Petersen F; Brun R; Dartois V; Diagana TT; Keller TH J Med Chem; 2010 Jul; 53(14):5155-64. PubMed ID: 20568778 [TBL] [Abstract][Full Text] [Related]
7. Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro. Sáenz FE; Mutka T; Udenze K; Oduola AM; Kyle DE Antimicrob Agents Chemother; 2012 Sep; 56(9):4685-92. PubMed ID: 22710117 [TBL] [Abstract][Full Text] [Related]
8. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Vaidya AB; Morrisey JM; Zhang Z; Das S; Daly TM; Otto TD; Spillman NJ; Wyvratt M; Siegl P; Marfurt J; Wirjanata G; Sebayang BF; Price RN; Chatterjee A; Nagle A; Stasiak M; Charman SA; Angulo-Barturen I; Ferrer S; Belén Jiménez-Díaz M; Martínez MS; Gamo FJ; Avery VM; Ruecker A; Delves M; Kirk K; Berriman M; Kortagere S; Burrows J; Fan E; Bergman LW Nat Commun; 2014 Nov; 5():5521. PubMed ID: 25422853 [TBL] [Abstract][Full Text] [Related]
9. Plasmodium berghei K13 Mutations Mediate Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP mBio; 2020 Nov; 11(6):. PubMed ID: 33173001 [TBL] [Abstract][Full Text] [Related]
10. Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil. Aguiar AC; Pereira DB; Amaral NS; De Marco L; Krettli AU Malar J; 2014 Feb; 13():73. PubMed ID: 24581308 [TBL] [Abstract][Full Text] [Related]
11. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. Flannery EL; McNamara CW; Kim SW; Kato TS; Li F; Teng CH; Gagaring K; Manary MJ; Barboa R; Meister S; Kuhen K; Vinetz JM; Chatterjee AK; Winzeler EA ACS Chem Biol; 2015 Feb; 10(2):413-20. PubMed ID: 25322084 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. Le Bihan A; de Kanter R; Angulo-Barturen I; Binkert C; Boss C; Brun R; Brunner R; Buchmann S; Burrows J; Dechering KJ; Delves M; Ewerling S; Ferrer S; Fischli C; Gamo-Benito FJ; Gnädig NF; Heidmann B; Jiménez-Díaz MB; Leroy D; Martínez MS; Meyer S; Moehrle JJ; Ng CL; Noviyanti R; Ruecker A; Sanz LM; Sauerwein RW; Scheurer C; Schleiferboeck S; Sinden R; Snyder C; Straimer J; Wirjanata G; Marfurt J; Price RN; Weller T; Fischli W; Fidock DA; Clozel M; Wittlin S PLoS Med; 2016 Oct; 13(10):e1002138. PubMed ID: 27701420 [TBL] [Abstract][Full Text] [Related]
13. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Meister S; Plouffe DM; Kuhen KL; Bonamy GM; Wu T; Barnes SW; Bopp SE; Borboa R; Bright AT; Che J; Cohen S; Dharia NV; Gagaring K; Gettayacamin M; Gordon P; Groessl T; Kato N; Lee MC; McNamara CW; Fidock DA; Nagle A; Nam TG; Richmond W; Roland J; Rottmann M; Zhou B; Froissard P; Glynne RJ; Mazier D; Sattabongkot J; Schultz PG; Tuntland T; Walker JR; Zhou Y; Chatterjee A; Diagana TT; Winzeler EA Science; 2011 Dec; 334(6061):1372-7. PubMed ID: 22096101 [TBL] [Abstract][Full Text] [Related]
14. Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol. Sato A; Hiramoto A; Morita M; Matsumoto M; Komich Y; Nakase Y; Tanigawa N; Hiraoka O; Hiramoto K; Hayatsu H; Higaki K; Kawai S; Masuyama A; Nojima M; Wataya Y; Kim HS Parasitol Int; 2011 Sep; 60(3):270-3. PubMed ID: 21501696 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. Deniskin R; Frame IJ; Sosa Y; Akabas MH Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473 [TBL] [Abstract][Full Text] [Related]
16. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. O'Neill PM; Amewu RK; Charman SA; Sabbani S; Gnädig NF; Straimer J; Fidock DA; Shore ER; Roberts NL; Wong MH; Hong WD; Pidathala C; Riley C; Murphy B; Aljayyoussi G; Gamo FJ; Sanz L; Rodrigues J; Cortes CG; Herreros E; Angulo-Barturén I; Jiménez-Díaz MB; Bazaga SF; Martínez-Martínez MS; Campo B; Sharma R; Ryan E; Shackleford DM; Campbell S; Smith DA; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Palmer MJ; Copple IM; Mercer AE; Ruecker A; Delves MJ; Sinden RE; Siegl P; Davies J; Rochford R; Kocken CHM; Zeeman AM; Nixon GL; Biagini GA; Ward SA Nat Commun; 2017 May; 8():15159. PubMed ID: 28537265 [TBL] [Abstract][Full Text] [Related]